Trial Profile

Individualizing therapy for neovascular age-related macular degeneration with aflibercept

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 01 Aug 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aflibercept (Primary)
Indications Wet age-related macular degeneration
Focus Therapeutic Use
Acronyms VITAL

Most Recent Events

22 May 2018 Status changed from active, no longer recruiting to completed.
06 Jul 2016 Status changed from recruiting to active, no longer recruiting.
11 Feb 2016 Accrual to date is 96% according to United Kingdom Clinical Research Network record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com